On Tuesday, Roth Capital revised its price target for Bio-Path Holdings Inc. (OTC:BPTH) to $2 from $9, while keeping a Buy rating on the shares. This adjustment came after the company provided an update on its clinical pipeline progress.
A scientist in a lab coat mixing the chemicals for the Liposomal Bcl-2 drug development.
In positive clinical developments, Bio-Path’s Prexigebersen achieved two complete responses in its Phase 2 trial for Acute Myeloid Leukemia/AML. This demonstrated continued treatment durability with over 15 treatment cycles and sustained complete remission. For its Phase 1 BP0012 trial, a patient in cohort 3 showed a 50% reduction of blast cells, which then led to enrollment in cohort 4.
Additionally, the Phase 1/1b clinical trial of BP1001-A in advanced solid tumors is progressing, with one patient in the second dose cohort showing a 15% reduction in her primary tumor. Preclinical studies for BP1001-A as a potential treatment for obesity in Type 2 Diabetes patients have also shown promise, with an IND application expected in 2025.
Bio-Path Holdings Inc. is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
Hedge Fund Resource Center